Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

ARV-393

Copy Product Info
😃Good
Catalog No. T84316Cas No. 2851885-95-3
Alias ARV393

ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL).

ARV-393

ARV-393

Copy Product Info
😃Good
Purity: 99.96%
Catalog No. T84316Alias ARV393Cas No. 2851885-95-3
ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL).
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$223-In Stock
5 mg$562-In Stock
10 mg$892-In Stock
25 mg$1,820-In Stock
50 mg$2,830-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.96%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL).
In vitro
ARV-393 demonstrated potent activity in multiple diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) cell lines, with both DC₅₀ and GI₅₀ values < 1 nM [1].
In vivo
In xenograft models, mice were orally administered ARV-393 (3, 10, 30 mg/kg; once daily; for 23 days) to evaluate its in vivo antitumor activity in lymphoma. ARV-393 significantly inhibited tumor growth. [2]
SynonymsARV393
Chemical Properties
Molecular Weight898.42
FormulaC46H53ClFN9O7
Cas No.2851885-95-3
SmilesFC1=C2C(C(=O)N(C2)C3C(=O)NC(=O)CC3)=CC=C1C4CCN(CC4)[C@@H]5C[C@@H](OC6CCN(CC6)C=7N=C(NC=8C=C9C(=CC8)N(C(C)C)C(=O)C(OCC(NC)=O)=C9)C(Cl)=CN7)C5
Relative Density.1.45 g/cm3 at 20℃ (Predicted)
Storage & Solubility Information
Storagekeep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 8 mg/mL (8.9 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.1131 mL5.5653 mL11.1307 mL55.6533 mL
5 mM0.2226 mL1.1131 mL2.2261 mL11.1307 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy ARV-393 | purchase ARV-393 | ARV-393 cost | order ARV-393 | ARV-393 chemical structure | ARV-393 in vivo | ARV-393 in vitro | ARV-393 formula | ARV-393 molecular weight